| Literature DB >> 35768845 |
Lijuan Zhang1, Beiwen Wu2, Junna Ye3.
Abstract
BACKGROUND: Systemic lupus erythematosus (SLE) might affect all aspects of life including sexual function; previous study indicated that fatigue was the risk factor of sexual dysfunction. The current study aims to investigate the effects of SLE on Chinese mainland female patients' sexual problems compared with healthy subjects and to investigate the relationship among fatigue, disease parameters, depression, quality of life and sexual problems in Chinese female patients with SLE.Entities:
Keywords: Chinese patients; Female; Female sexual problems; Systemic lupus erythematosus
Mesh:
Substances:
Year: 2022 PMID: 35768845 PMCID: PMC9245321 DOI: 10.1186/s12905-022-01854-3
Source DB: PubMed Journal: BMC Womens Health ISSN: 1472-6874 Impact factor: 2.742
Demographic characteristics in SLE patients and health controls
| Variables | SLE patients (n = 128) | Health controls (n = 121) | |
|---|---|---|---|
| Age (years) | 43.65 ± 7.13 | 43.59 ± 6.57 | 0.944 |
| BMI (kg/m2) | 23.12 ± 4.15 | 23.06 ± 3.35 | 0.902 |
| Marital status | 0.784 | ||
| Single/divorced/widowed | 31 (24.2) | 28 (23.1) | |
| Married | 97 (75.8) | 93 (76.9) | |
| Having child (yes) | 92 (71.8) | 88 (72.7) | 0.787 |
| Education | 0.992 | ||
| Primary and below | 25 (19.5) | 23 (19.0) | |
| Secondary | 30 (23.4) | 29 (24.0) | |
| Graduate and above | 73 (57.1) | 69 (57.0) | |
| Employment status | 0.379 | ||
| Unemployed | 64 (50.0) | 71 (57.8) | |
| Employed | 64 (50.0) | 50 (42.2) | |
| Income/person/month | 0.678 | ||
| ≤ 3000 Yuan | 2 (1.6) | 2 (1.7) | |
| 1000–3000 yuan | 28 (21.9) | 24 (19.8) | |
| 3000–5000 yuan | 35 (27.3) | 33 (27.3) | |
| ≥ 5000 yuan | 63 (49.2) | 62 (51.2) | |
| Health insurance (yes) | 109 (85.2) | 102 (84.3) | 0.756 |
| Religious beliefs (yes) | 17 (13.3) | 11 (9.1) | 0.262 |
| Residence | 0.145 | ||
| Urban | 114 (89.1) | 100 (82.6) | |
| Rural | 14 (10.9) | 21 (17.4) |
Data are presented as mean ± SD or number (%)
SLE Systemic Lupus Erythematosus, BMI Body mass index
Fig. 1Comparison of the subscale and total scores of FSFI in SLE patients and controls. *P < 0.05; **P < 0.01
The comparison between SLE patients with and without sexual dysfunction concerning the demographic and clinic characteristics, and the different indices
| Variables | With sexual dysfunction (n = 101) | Without sexual dysfunction (n = 27) | ||
|---|---|---|---|---|
| Age (years) | 40.90 ± 13.50 | 36.37 ± 6.84 | 2.44 | 0.018* |
| BMI (kg/m2) | 23.14 ± 4.28 | 23.02 ± 3.69 | 0.13 | 0.896 |
| Marital status | 10.94 | 0.001** | ||
| Single/divorced/widowed | 30 (29.7) | 1 (3.7) | ||
| Married | 70 (70.3) | 26 (96.3) | ||
| Having child (yes) | 68 (67.3) | 24 (88.9) | 4.90 | 0.027* |
| Education | 0.01 | 0.973 | ||
| Primary and below | 20 (19.8) | 4 (14.8) | ||
| Secondary | 29 (28.7) | 9 (33.3) | ||
| Graduate and above | 52 (51.5) | 14 (51.9) | ||
| Employment status | 1.17 | 0.279 | ||
| Unemployed | 53 (52.5) | 11 (40.7) | ||
| Employed | 48 (47.5) | 16 (59.3) | ||
| Income/person/month | 0.78 | 0.379 | ||
| ≤ 1000 Yuan | 2 (2.0) | 0 (0) | ||
| 1000–3000 yuan | 23 (22.8) | 5 (18.5) | ||
| 3000–5000 yuan | 28 (27.7) | 7 (25.9) | ||
| ≥ 5000 yuan | 48 (47.5) | 15 (55.6) | ||
| Health insurance (yes) | 86 (85.1) | 23 (85.2) | 0.01 | 0.996 |
| Religious beliefs (yes) | 13 (12.9) | 4 (14.8) | 0.07 | 0.792 |
| History of hospitalization (yes) | 81 (80.2) | 20 (74.1) | 0.48 | 0.488 |
| History of family (yes) | 14 (13.9) | 1 (3.7) | 2.13 | 0.145 |
| Comorbid condition (yes) | 62 (61.4) | 12 (44.4) | 2.51 | 0.113 |
| Residence | 0.01 | 0.974 | ||
| Urban | 90 (89.1) | 24 (88.9) | ||
| Rural | 11 (10.9) | 3 (11.1) | ||
| SLE disease duration (years) | 6.39 ± 7.22 | 3.80 ± 2.77 | 2.89 | 0.005** |
| VAS pain (range 0–10) | 2.00 ± 1.50 | 1.67 ± 1.14 | 1.07 | 0.286 |
| SLEDAI | 6.28 ± 7.88 | 2.78 ± 3.64 | 3.33 | 0.001** |
| DMARDs usage (yes) | 73 (72.3) | 26 (96.3) | 7.01 | 0.008** |
| Corticosteroid usage (yes) | 84 (83.2) | 23 (85.2) | 0.01 | 0.802 |
| Biologics usage (yes) | 18 (17.8) | 8 (29.6) | 1.84 | 0.176 |
| Depression (PHQ9) | 5.27 ± 4.88 | 2.81 ± 4.54 | 2.35 | 0.020* |
| Fatigue (MFI) | ||||
| General fatigue | 12.12 ± 3.09 | 10.67 ± 3.36 | 2.13 | 0.035* |
| Physical fatigue | 12.37 ± 3.53 | 10.67 ± 2.98 | 2.29 | 0.024* |
| Mental fatigue | 10.42 ± 3.67 | 8.12 ± 3.54 | 2.83 | 0.005** |
| Reduced motivation | 9.35 ± 2.87 | 8.56 ± 3.30 | 1.23 | 0.220 |
| Reduced activity | 11.67 ± 3.03 | 9.96 ± 4.00 | 2.01 | 0.046* |
| Total score | 56.43 ± 13.05 | 48.04 ± 13.51 | 2.95 | 0.004** |
| Quality of life (SF-12) | ||||
| PCS | 44.11 ± 8.85 | 47.48 ± 7.91 | − 1.80 | 0.075 |
| MCS | 45.96 ± 5.77 | 46.39 ± 4.82 | − 0.36 | 0.720 |
| Total score | 90.06 ± 9.29 | 93.87 ± 8.07 | − 1.94 | 0.046* |
Data are presented as mean ± SD or number (%)
SLE Systemic Lupus Erythematosus, BMI Body Mass Index, VAS Visual Analog Scale, SLEDAI Systemic Lupus Erythematosus Disease Activity Index, DMARDs Disease-Modifying Anti-rheumatic Drugs, PDD Perceived Devaluation-Discrimination, PHQ-9 Patient Health Questionnaire-9, MFI Multiple Fatigue Inventory, SF-12 Short Form 12 health survey, PCS physical components summary, MCS mental components summary
*P < 0.05; **P < 0.01
Result of analysis of forward stepwise ordered logit regression models in SLE patients
| Variables | B | SE | Exp (B) | 95% CI | ||
|---|---|---|---|---|---|---|
| Lower | Higher | |||||
| Step 1 | ||||||
| MFI total score | 0.05 | 0.02 | 0.005** | 1.05 | 1.01 | 1.09 |
| Step 2 | ||||||
| DMARDs usage | − 2.36 | 1.05 | 0.025* | 0.10 | 0.01 | 0.75 |
| MFI total score | 0.05 | 0.02 | 0.005** | 1.05 | 1.01 | 1.09 |
| Step 3 | ||||||
| DMARDs usage | − 2.58 | 1.06 | 0.015* | 0.08 | 0.01 | 0.61 |
| MFI total score | 0.04 | 0.02 | 0.026* | 1.04 | 1.01 | 1.08 |
| Disease duration | 0.12 | 0.06 | 0.035* | 1.13 | 1.01 | 1.26 |
| Step 4 | ||||||
| Having child | − 1.45 | 0.63 | 0.031* | 0.19 | 0.06 | 0.97 |
| DMARDs usage | − 2.88 | 1.11 | 0.009** | 0.13 | 0.01 | 0.87 |
| MFI total score | 0.05 | 0.02 | 0.005** | 1.07 | 1.00 | 1.12 |
| Disease duration | 0.13 | 0.06 | 0.039* | 1.14 | 1.02 | 1.30 |
| Step 5 | ||||||
| Age | 0.11 | 0.04 | 0.002** | 1.11 | 1.04 | 1.19 |
| Having child | − 1.57 | 0.70 | 0.024* | 0.21 | 0.05 | 0.81 |
| DMARDs usage | − 3.28 | 1.16 | 0.004** | 0.04 | 0.01 | 0.36 |
| MFI total score | 0.06 | 0.02 | 0.006** | 1.06 | 1.02 | 1.10 |
| Disease duration | 0.15 | 0.07 | 0.043* | 1.16 | 1.00 | 1.34 |
SLE Systemic Lupus Erythematosus, DMARDs Disease-Modifying Anti-rheumatic Drugs, MFI Multiple Fatigue Inventory, OR odds ratio, CI confidence interval
*P < 0.05; **P < 0.01